Renin inhibitors are a new direction in the treatment of arterial hypertension


Cite item

Full Text

Abstract

The paper covers current problems in the treatment of arterial hypertension. Renin is an important and promising therapeutic target. The direct renin inhibitor aliskiren (Rasilez) is a promising current effective antihypertensive agent that has cardio- and nephroprotective effects. The paper considers a number of clinical studies that have proven the antihypertensive effect of aliskiren and revealed its benefits versus other drugs recommended for blood pressure lowering. It is assumed that this agent may be used in combinations with angiotensin-converting enzyme inhibitors, thiazide or thiazide-like diuretics, and calcium antagonists. Moreover, aliskiren neutralizes the effect of feedback in the compensatory increase in the activity of plasma renin.

References

  1. Белоконева О. На подступах к ренину: 110 лет поиска. Наука и жизнь 2008; 6: 15-20.
  2. Мухин Н. А., Фомин В. В. Ренин - мишень прямой фармакологической блокады при артериальной гипертонии. Тер. арх. 2009; 8: 5-9.
  3. Серов В. В., Пальцев Н. А. Почки и артериальная гипертензия. М.: Медицина; 1993.
  4. Skott O. Renin. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002; 282: 937-939.
  5. Persson P. B. Renin: origin, secretion and synthesis. J. Physiol. (Lond.) 2003; 552(3): 667-671.
  6. Chen M., Schnermann J., Smart A. M. et al. Cyclic AMP selectively increases renin mRNA stability in cultured juxtaglomerular granular cells. J. Biol. Chem. 1993; 268: 24138-24144.
  7. Friis U. G., Jensen B. L., Sethi S. et al. Control of renin secretion from ras juxtaglomerular cells by cAMP-specific phosphodiesterases. Circ. Res. 2002; 90: 996-1003.
  8. Friis U. G., Jorgensen F., Andreasen D. et al. Molecular and functional identification of cyclic AMP-sensitive BKCa potassium channels (ZEROvariant) and L-type voltagedependent calcium channels in single ras juxtaglomerular cells. Circ. Res. 2003; 93: 213-220.
  9. Kurtz A., Delia Bruna R., Pfeilschifler J. et al. Atria I natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. Proc. Natl. Acad. Sci. USA 1986; 83(13): 4769-4773.
  10. Rummery N. M., Hill C. E. Vascular gap junctions and implications for hypertension. Clin. Exp. Pharmacol. Physiol. 2004; 31(10): 659-667.
  11. Wagner C. Function of connexins in the renal circulation. Kidney Int. 2008; 73(5): 547-555.
  12. Gomez R. A., Sequeira Lopez M. L. Who and where is the renal baroreceptor? The connexin hypothesis. Kidney Int. 2009; 75(5): 460-462.
  13. Takahashi H., Murakami K., Miyake Y. Activation of kidney prorenin by kidney kathepsin B isozymes. J. Biochem. (Tokyo) 1982; 91: 419-422.
  14. Jan Danser A. H., Batnburg W. W., van Esch J. H. M. Prorenin and the (pro)renin receptor - an update. Nephrol. Dial. Transplant 2007; 22: 1288-1292.
  15. Kaneshiro Y., Ichihara A., Sacoda M. et al. Slowly progressive, angiotensin II - independent glomerulosclerosis in human pro(renin) receptor-transgenic rats. J. Am. Soc. Nephrol. 2007; 18: 1789-1795.
  16. Nguyen G., Delarue F., Burckle C. et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 2002; 109: 1417-1427.
  17. Huang Y., Wongamorntham S., Kasting J. et al. Renin increases mesangial cell transforminggrowthfactor-betalandmatrixproteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006; 69: 105-113.
  18. Sakoda M., Ichihara A., Kaneshiro Y. et al. (Pro)renin receptor-mediated activation of mitogenactivated protein kinases in human vascular smooth muscle cells. Hypertens. Res. 2007; 30: 1139-1146.
  19. Nguyen G., Danser A. H. J. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp. Physiol. 2008; 93(5): 557-563.
  20. Ichihara A., Suzuki F., Nakagawa T. et al. Prorenin receptor blockade inhibitsdevelopment of glomerulosclerosis in diabetic angiotensin II type la receptor-deficient mice. J. Am. Soc. Nephrol. 2006; 17: 1950-1961.
  21. Takahashi H., Ichihara A., Kaneshiro Y. et al. Regression of nephropathy developed in diabetes by (Pro)renin receptor blockade. J. Am. Soc. Nephrol. 2007; 18: 2054-2061.
  22. Krebs C., Hamming I., Sadaghiani S. et al. Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int. 2007; 72: 725-730.
  23. Danser A. H. J., Deinum J. Renin, prorenin and the putative prorenin receptor. Hypertension 2005; 46: 1069-1076.
  24. Oliver J. A. Receptor mediated actions of renin and pro-renin. Kidney Int. 2006; 69: 13-15.
  25. Alderman M. H., Ooi W. L. Plasma renin activity: A risk factor for myocardial infarction in hypertensive patients/ Am. J. Hypertens. 1997; 10: 1-8.
  26. Struthers A. D. Aldosterone blockade in cardiovascular disease. Heart 2004; 90: 1229-1234.
  27. Duprez D. A. Role of renin-angiotensin aldosterone system in vascular remodeling and inflammation: a clinical review. J. Hypertens. 2006; 24: 983-991.
  28. Mulatero P., Milan A., Williams T. A. et al. Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc. Hematol. Agents Med. Chem. 2006; 4: 75-91.
  29. Sato A., Hayashi K., Naruse M. et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68.
  30. Junick P. C., Lewis S. Y., Brody M. Y. Role of central mineralocorticoid binding sites in development of hypertension. Am. J. Physiol. 1990; 259: 1025-1034.
  31. Weber K. T., Brilla C. G. Myocardial fibrosis and the renin-angiotensin-aldosterone system. J. Cardiovasc. Pharmacol. 1992; 20: 48-54.
  32. Borghi C., Boschi S., Ambrosioni E. et al. Evidence of a partial escape from renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. Clin. Pharmacol. 1993; 33: 40-45.
  33. MacFadyen R. J., Lee A. F., Morton J. et al. How often are angiotensin II and aldosterone levels raised during chronic ACE inhibitor treatment in chronic heart failure? Heart 1999; 82: 57-61.
  34. Odedra K., Ferro A. Neurohormones, aldosterone, and heart failure: Aldosterone and heart failure. Int. J. Clin. Pract. 2006; 60(7): 835-846.
  35. Vantrimpont P., Rouleau J. L., Ciampi A. et al. Two-year time and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) study. Eur. Heart J. 1998; 19(10): 1552-1563.
  36. Sato A., Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J. Int. Med. Res. 2001; 29: 13-21.
  37. Verma A., Juszczynska K., Uno H. et al. Neurohumoral effects of an oral direct renin inhibitor in patients with left ventricular hypertrophy: the Aliskiren in Left Ventricular Hypertrophy (ALLAY) trial. In: ESH congress materials, Milan, Italy, 12- 16 June 2009. Milan; 2009. S 314, abstr. 7B.4.
  38. Swedbefg K., Eneroth P., Kjekshus J., Wilhelmsen L. For the CONSENSUS Trial Study Group. Hormones regulating cardio-vascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-1736.
  39. Минушкина Л. О., Затейщикова А. А., Хотченкова Н. В. и др. Активность ренин-ангиотензин-альдостероновой системы и особенности структуры и функции миокарда левого желудочка у больных артериальной гипертонией. Кардиология 2000; 9: 23-26.
  40. Denolle T., Chatellier G., Julien J. et al. Left ventricular mass and geometry before and after treatment in renovascular hypertension, aldosterone producing adenoma, and pheochromocytoma. Am. J. Hypertens. 1993; 6: 907-913.
  41. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994; 24: 571-575.
  42. Бражник В. А., Затейщиков Д. А., Сидоренко Б. А. Наследственные факторы и гипертрофия левого желудочка. Кардиология 2003; 1: 78-88.
  43. Mazzolai L., Korber M., Aubert J. F. et al. Renin inhibitor, aliskiren, prevents vulnerable plaque development in a mouse model of unstable plaque. Eur. Heart J. 2005; 26(Suppl.): 296.
  44. Чазова И. Е., Фомин В. В., Пальцева Е. М. Прямой ингибитор ренина алискирен - новые возможности защиты почек при артериальной гипертензии. Клин. нефрол. 2009; 1: 5-7.
  45. Lu H., Rateri D. I., Feldman D. L. et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J. Clin. Invest. 2008; 118: 984-993.
  46. Vaidyanathan S., Jarugula V., Dieterich H. A., et al. Clinical pharmacodynamics of aliskiren. Clin. Pharmacokinet. 2008; 48(8): 515-531.
  47. Gradman A. H., Schmieder R. E., Lins R. L. et al. Alisklren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-10l8.
  48. Uresin Y., Taylor A. A., Kilo C. et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin Angiotensin Aldosterone Syst. 2007; 8: 190-198.
  49. Tschoepe D., Taylor A., Kilo C. et al. Aliskiren, alone and in combination with ramipril, significantly lowers blood pressure and plasma renin activity in patients with diabetes and hypertension, regardless of the degree of glycaemic control. Diabetologia 2006; 49(Suppl.): 136-217.
  50. Taylor A. A., Anderson D. R., Arora V. et al. Renin system suppression with the oral direct renin inhibitor aliskiren administered alone or in combination: a pooled analysis of 1093 patients with hypertension. J. Am. Coll. Cardiol. 2007; 49(9, Suppl. A): 370.
  51. Calhoun D., Chrysant S., Villamil A. et al. The novel oral renin inhibitor aliskiren decreases plasma renin activity (PRA) and neutralizes hydrochlorothiazide-induced RAAS activation in hypertensive patients. J. Clin. Hypertens. 2006; 8 (Suppl. A): A 77, 168.
  52. Drummond W., Munger M. A., Essop M. R. et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J. Clin. Hypertens. 2007; 9: 742-750.
  53. Parving H. H., Persson F., Lewis J. B. et al. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 2008; 358(23): 2433- 2446.
  54. Solomon S. D., Appelbaum E., Manning W. J. et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119(4): 530-537.
  55. McMurray J. J. V., Pitt B., Latini R. et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation Heart Fail. 2008; 1: 17-24.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies